Skip to main content
main-content

25.07.2017 | Retinal Disorders | Ausgabe 11/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2017

ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up

Zeitschrift:
Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 11/2017
Autoren:
Alicia Valverde-Megías, Silvia Veganzones-de-Castro, Juan Donate-López, Maria Luisa Maestro-de-las-Casas, Alicia Megías-Fresno, Julián García-Feijoo

Abstract

Purpose

To investigate whether single-nucleotide polymorphisms (SNPs) known to be strongly associated with the development of age-related macular degeneration (AMD) have an influence on recurrence rate of choroidal neovascularization (CNV) activity during 4-year ranibizumab treatment for exudative AMD.

Methods

This prospective study included 103 treatment-naïve patients (103 eyes) that received initially a loading dose of 3 monthly ranibizumab injections and thereafter, were treated according to an as-needed regimen for a 4-year follow-up period. Baseline values, visual outcome, and recurrence rate were examined. CFH Y402H and ARMS2 A69S polymorphisms were determined and their association with lesion recurrence and visual outcome was analyzed using a one-way analysis of variance (ANOVA) with post hoc comparison tested by Fisher’s LSD method. Multivariate linear regression analysis was then used to identify factors associated with recurrence rate.

Results

The cumulative total mean number of ranibizumab injections at the end of each year of the follow-up was 5.3 ± 1.8, 9.2 ± 2.9, 12.6 ± 4.6, and 15.7 ± 6.1. There was great inter-patient variability. Nineteen eyes (18.5%) did not experience recurrence during the first year, and five (4.8%) still displayed inactive CNV after 4 years of follow-up. No significant association was found between the number of injections and mean best corrected visual acuity (BCVA) change or final BCVA at the end of the study period. Genotypes had no influence on baseline characteristics or visual outcome but a significant association was found between the A69S polymorphism and the number of injections needed by the patients. Homozygous for the T risk allele required more retreatments over the 48-month follow-up.

Conclusions

The ARMS2 A69S polymorphism was associated with CNV recurrence rate in our patient cohort. Prediction of a greater risk of recurrence could help to design more appropriate follow-up treatment strategies for patients with neovascular AMD.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Bis zum 22.10. bestellen und 100 € sparen!

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2017Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

06.07.2018 | Leitthema | Ausgabe 9/2018 Open Access

Screening und Management retinaler Erkrankungen mittels digitaler Medizin

06.07.2018 | Leitlinien, Stellungnahmen und Empfehlungen | Ausgabe 8/2018

Empfehlungen der DOG für die Planung klinischer Studien im Auftrage Dritter

März 2018

29.06.2018 | Das therapeutische und diagnostische Prinzip | Ausgabe 8/2018

Neuer Glaskörperersatz mit Hydrogel?

 

 

 
 

Bildnachweise